What Is Wegovy Used For: Clinical Applications and Personalized Treatment Context

Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist approved by the FDA in 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Clinical trials showed approximately 15% average weight loss over 68 weeks compared to 2.4% with placebo.

Beyond brand-name options, patients benefit from understanding how their individual biology—including genetic predispositions in GLP-1 and metabolic pathways—may influence treatment response. PlexusDx supports precision wellness by offering genetic insights and compounded alternatives that help personalize the conversation with your healthcare provider.

How GLP-1 Receptor Agonists Work in Weight Management

Wegovy activates GLP-1 receptors in the brain's appetite centers, increasing satiety signals and reducing hunger. It also slows gastric emptying, extending feelings of fullness after meals and helping reduce overall calorie intake without requiring strict dieting protocols.

The medication also influences glucose homeostasis and may improve cardiovascular outcomes in patients with established cardiovascular disease. This dual mechanism—appetite suppression plus metabolic benefits—distinguishes GLP-1 agonists from older weight-loss medications and contributes to their sustained clinical effectiveness.

Approved Clinical Indications and Patient Eligibility Framework

Wegovy is indicated for chronic weight management in adults with obesity or overweight with weight-related comorbidities such as hypertension, type 2 diabetes, or cardiovascular disease. Individual provider assessment determines candidacy based on medical history, contraindications, and treatment goals.

Clinical Indication	BMI Threshold	Key Consideration
Obesity without comorbidities	≥30 kg/m²	Approved use; requires provider evaluation
Overweight with hypertension	≥27 kg/m² + condition present	Weight-related condition must be documented
Overweight with type 2 diabetes	≥27 kg/m² + diabetes diagnosis	Metabolic benefit may be pronounced
Overweight with cardiovascular disease	≥27 kg/m² + CVD history	Provider assessment required; cardiovascular benefit possible

Biomarkers and Individual Response Variation in GLP-1 Therapy

Not all patients respond identically to GLP-1 agonists. Genetic variations in the GLP1R gene (rs6923761) and GIPR gene (rs1800437) influence receptor function and may correlate with differential treatment response. Additionally, genetic variants in metabolic genes like FTO (rs9939609) and MC4R (rs17782313) relate to baseline weight regulation capacity.

Understanding these predispositions in your peptide signaling pathways can help inform a more targeted conversation with your provider about dosing, timing, and whether a GLP-1 agonist aligns with your individual biology. PlexusDx's Precision Peptide Genetic Test reveals these predispositions—though genetics is one input among many clinical factors, not a predictor of exact medication response.

Safety, Contraindications, and Provider Guidance Before Starting

Wegovy carries important safety warnings, including risk of pancreatitis, gallbladder disease, and diabetic retinopathy changes. It is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Thyroid monitoring may be recommended during treatment.

A thorough medical evaluation by a qualified healthcare provider is essential before initiating any GLP-1 agonist therapy. Your provider will assess your complete medical history, current medications, and individual risk profile to determine whether Wegovy or a compounded GLP-1 alternative is appropriate for your clinical situation and treatment goals.

How PlexusDx Supports a More Personalized Approach

PlexusDx's approach to GLP-1 therapy emphasizes personalization through genetic predisposition testing. Our Precision Peptide Genetic Test evaluates variants in GLP1R, GIPR, FTO, and MC4R—genes that influence GLP-1 signaling, appetite regulation, and baseline metabolic capacity. This information may help provide context for your provider conversation, though it reflects predispositions, not guaranteed medication response.

Understanding your peptide pathway genetics can support a more nuanced discussion about whether branded Wegovy, compounded semaglutide, tirzepatide, or other GLP-1 options align best with your biology and goals. For example, patients with specific GLP1R variants may have different baseline sensitivity to GLP-1 signaling, which could inform dosing or medication selection conversations with your provider.

PlexusDx compounded semaglutide ($149/mo) and compounded tirzepatide ($249/mo) offer cost-effective, personalized alternatives sourced from licensed 503A compounding pharmacies. When combined with genetic insights and provider guidance, this integrated approach can support more informed, individualized treatment decisions than brand-name options alone.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Wegovy approved only for weight loss, or does it have other clinical uses?

Wegovy is FDA-approved specifically for chronic weight management in adults with obesity or overweight plus weight-related conditions. However, the same active ingredient (semaglutide) is also approved as Ozempic for type 2 diabetes and Rybelsus for oral use. Your provider determines the appropriate indication and formulation.

How much weight can someone expect to lose with Wegovy?

Clinical trials showed average weight loss of approximately 15% body weight over 68 weeks with Wegovy, compared to 2.4% with placebo. Individual results vary significantly based on baseline metabolism, adherence, lifestyle factors, and genetic predispositions in weight regulation pathways.

What is the typical cost of Wegovy, and are there more affordable alternatives?

Wegovy typically costs $300–$500+ monthly without insurance coverage. PlexusDx offers compounded semaglutide from $149/mo and compounded tirzepatide from $249/mo through licensed 503A pharmacies, providing cost-effective alternatives. Discuss availability and coverage with your provider.

Can the Precision Peptide Genetic Test predict whether Wegovy will work for me?

No. The Precision Peptide Genetic Test reveals predispositions in GLP-1 and metabolic pathways but does not predict exact medication response. Genetics is one factor among many—including lifestyle, adherence, comorbidities, and individual physiology. Use test results to support a more informed conversation with your provider.

Who should not take Wegovy or GLP-1 agonists?

GLP-1 agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Caution is advised in those with pancreatitis history, gallbladder disease, severe kidney disease, or diabetic retinopathy. Your provider will assess your complete medical history to determine elig...